Leuven, Belgium

Lukas Van Oudenhove

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Compagnie Gervais Danone. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lukas Van Oudenhove: Innovator in Anxiety and Stress Amelioration

Introduction

Lukas Van Oudenhove is a notable inventor based in Leuven, Belgium. He has made significant contributions to the field of mental health through his innovative work. His research focuses on the amelioration of anxiety and psychological stress, which is increasingly relevant in today's fast-paced world.

Latest Patents

Lukas holds a patent for a composition aimed at the prevention, amelioration, or treatment of anxiety and/or psychological stress in individuals. This composition includes CNCM I-3690, showcasing his commitment to developing effective solutions for mental health challenges. He has 1 patent to his name, reflecting his innovative approach to addressing these issues.

Career Highlights

Throughout his career, Lukas has worked with prominent companies such as Compagnie Gervais Danone and Société des Produits Nestlé S.A. His experience in these organizations has undoubtedly enriched his expertise and contributed to his innovative endeavors.

Collaborations

Lukas has collaborated with talented individuals in his field, including Tamara Smokvina and Raphaël Moriez. These partnerships have likely fostered a creative environment that encourages the development of groundbreaking ideas.

Conclusion

Lukas Van Oudenhove is a dedicated inventor whose work in the field of anxiety and stress amelioration is both impactful and necessary. His contributions through patents and collaborations highlight his commitment to improving mental health solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…